Summary of Proposal:
A Message from the Cellestis Board of Directors
Dear Cellestis Shareholders,
In the Scheme meeting on 3 August 2011, Cellestis shareholders were asked to consider and vote on a preliminary resolution and an amended scheme resolution for Cellestis shareholders to receive total cash payments of A$3.80 per Cellestis share under the Scheme. At the Scheme meeting, a majority of your fellow shareholders approved the proposal for Cellestis to be acquired in its entirety by QIAGEN Australia Holding Pty Limited, a subsidiary of QIAGEN N.V., with over 92% of votes cast in favour of each proposal and with over 80% of Cellestis shareholders that voted at the Scheme meeting voting in favour of each proposal.
On 9 August 2011, the Supreme Court of Victoria made orders approving the scheme of arrangement between Cellestis and Cellestis shareholders (other than Excluded Shareholders), to effect the acquisition of Cellestis by QIAGEN Australia Holding Pty Limited. With this confirmation, Cellestis and QuantiFERON are now ready to progress to a new chapter in a very successful story.
As founding Directors of Cellestis, we would like to thank you, as Cellestis shareholders, for your support of the company since its ASX listing in April 2001. Throughout this time, we’ve been amazed and have always appreciated the enthusiasm and passion which you have demonstrated for Cellestis and QuantiFERON.
We thank you for this support.
Cellestis Board of Directors
